Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$942.25M
• Dividend Yield: 1.98%
• Average Volume (3M): 1.39M
• Price to Earnings (P/E): 104.1
• Beta (1Y): 0.11
• Revenue Growth: 7.83%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 372,429,530
• 10 Day Avg. Volume: 1,932,571
• 30 Day Avg. Volume: 1,389,498
• PEG Ratio: 0.53
• Price to Book (P/B): 2.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 27.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.55
• Price Target Upside: 40.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 53 Neutral
• Price Target: AU$2.50 ▼(-1.19%Downside)

The overall stock score reflects a mixed financial performance with robust revenue growth and cash management but significant profitability challenges. Technical indicators are neutral, pointing to mild momentum without strong buying or selling signals. The high P/E ratio highlights valuation concerns, suggesting the stock may be overvalued, which impacts the overall attractiveness.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Integral Diagnostics Ltd. generates revenue primarily through the provision of diagnostic imaging services. The company's key revenue streams include fees charged for imaging procedures such as X-rays, MRIs, CT scans, and other radiology services. These services are offered to patients directly, as well as through partnerships with healthcare providers, hospitals, and medical practitioners who refer their patients for imaging diagnostics. Additionally, IDX may have agreements with health insurance providers, which reimburse the company for services provided to insured patients. The company's earnings are further supported by its strategic location of clinics in populous areas, ensuring a steady flow of patients, and by leveraging cutting-edge imaging technology to provide efficient and accurate diagnostics.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. demonstrates robust revenue growth and efficient cash management. However, significant challenges are evident in profitability, with negative net income and deteriorating EBIT margins. High leverage and negative return on equity indicate financial risks.

Income Statement

The company shows mixed results in its income statement. Gross profit margin is high at 95.12%, indicating effective cost management relative to revenue. However, the net profit margin is negative due to a net loss, which is a significant concern. Revenue growth is strong at 6.72% year-over-year, demonstrating a positive trend in sales. However, EBIT and EBITDA margins have declined sharply, reflecting operational challenges.

Balance Sheet

The balance sheet presents a stable financial position with an equity ratio of 40.54%, indicating a solid equity base. However, the debt-to-equity ratio is high at 1.19, pointing to significant leverage that could pose risks in challenging economic conditions. Return on Equity has turned negative due to the net loss, highlighting profitability issues.

Cash Flow

The cash flow statement reveals steady operational cash flows with an operating cash flow to net income ratio of -1.09, indicating strong cash generation relative to net income despite losses. Free cash flow growth is significant at 54.21%, showcasing effective cash management, but free cash flow to net income ratio is negative, underscoring profitability concerns.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	491.32M	469.70M	440.10M	358.74M	348.81M	274.08M
Gross Profit	130.74M	446.78M	97.76M	83.84M	92.19M	72.06M
EBITDA	78.95M	12.33M	92.74M	69.90M	88.94M	69.50M
Net Income	5.66M	-60.70M	25.04M	14.60M	31.27M	23.03M
Balance Sheet
Total Assets	1.36B	744.28M	839.01M	783.01M	654.90M	586.91M
Cash, Cash Equivalents and Short-Term Investments	31.26M	42.44M	33.85M	123.19M	62.20M	57.97M
Total Debt	532.65M	357.80M	365.08M	340.99M	308.36M	277.85M
Total Liabilities	665.27M	442.57M	465.96M	435.77M	400.16M	358.58M
Stockholders Equity	693.17M	301.71M	373.05M	347.24M	254.74M	228.33M
Cash Flow
Free Cash Flow	34.15M	42.28M	27.42M	9.33M	49.30M	28.37M
Operating Cash Flow	73.12M	66.16M	71.42M	37.10M	69.57M	54.25M
Investing Cash Flow	-44.45M	-27.90M	-128.96M	-55.69M	-56.66M	-93.53M
Financing Cash Flow	-14.87M	-29.45M	-31.85M	81.13M	-7.83M	75.40M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.53 is above the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.40, and below the 200-day MA of 2.67, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 65.81 is Neutral, neither overbought nor oversold. The STOCH value of 72.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDX	53 Neutral	AU$942.25M	104.12	1.14%	1.98%	7.83%	―
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
PGZ		€303.40M	―	-4.46%	―	―	―
SHL	73 Outperform	AU$13.21B	23.46	6.86%	3.29%	10.15%	6.20%
ACL	58 Neutral	AU$542.04M	17.93	18.39%	2.54%	7.80%	99.87%
MVF	52 Neutral	AU$280.54M	―	-0.87%	7.12%	14.24%	-109.59%
GSS	45 Neutral	AU$86.31M	―	-47.52%	―	44.61%	16.40%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics CEO Announces Retirement, Initiates Leadership Transition

Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Present at 2025 Macquarie Australia Conference

Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics

Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.

Integral Diagnostics Announces Change of Registered Office

Integral Diagnostics Ltd. has announced a change in its registered office and principal place of business to a new location in East Melbourne, effective 17 April 2025. This change reflects the company’s ongoing commitment to maintaining efficient operations and potentially enhancing its service delivery capabilities.

Integral Diagnostics Announces Cessation of Securities

Integral Diagnostics Ltd. announced the cessation of certain securities, specifically 50,871 performance rights under LTI and 10,101 under STI, due to unmet conditions. This cessation may impact the company’s financial structuring and stakeholder interests, reflecting on the company’s operational strategies and market positioning.

Integral Diagnostics Director Increases Shareholding

Integral Diagnostics Ltd. announced a change in the director’s interest, with James Tobias Hall acquiring an additional 2,088 fully paid ordinary shares through the company’s Dividend Reinvestment Plan. This acquisition reflects a modest increase in the director’s holdings, potentially signaling confidence in the company’s future performance and aligning with shareholder interests.

Integral Diagnostics Announces Quotation of New Securities

Integral Diagnostics Ltd. has announced the application for quotation of 610,566 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and offering opportunities for stakeholders to engage with the company’s growth strategy.